{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:42:03Z","timestamp":1788914523033,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40265-021-01479-0","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T09:05:48Z","timestamp":1615626348000},"page":"509-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Tirbanibulin: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"issue":"11","key":"1479_CR1","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","volume":"61","author":"MP Smolinski","year":"2018","unstructured":"Smolinski MP, Bu Y, Clements J, et al. Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361). J Med Chem. 2018;61(11):4704\u201319.","journal-title":"J Med Chem."},{"key":"1479_CR2","doi-asserted-by":"crossref","unstructured":"Kasner MT, Ritchie EK, Cutler D, et al. A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy [abstract no. 7043]. J Clin Oncol. 2017;35(15 (Suppl 1)).","DOI":"10.1200\/JCO.2017.35.15_suppl.7043"},{"issue":"4","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","volume":"71","author":"ES Antonarakis","year":"2013","unstructured":"Antonarakis ES, Heath EI, Posadas EM, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71(4):883\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1479_CR4","unstructured":"Kinex Pharmaceuticals L. L. C., Hanmi Pharmaceutical. Kinex Pharmaceuticals and Hanmi Pharmaceutical announce first patient has been enrolled in phase 1b\/IIa clinical trial in Korea [media release]. 7 Jan 2013. http:\/\/www.kinexpharma.com."},{"issue":"4","key":"1479_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s10637-013-9929-8","volume":"31","author":"A Naing","year":"2013","unstructured":"Naing A, Cohen R, Dy GK, et al. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Investig New Drugs. 2013;31(4):967\u201373.","journal-title":"Investig New Drugs."},{"key":"1479_CR6","unstructured":"Athenex. Athenex pipeline, Src kinase inhibition. 2021. https:\/\/www.athenex.com\/pipeline\/orascovery-platform\/src-kinase-inhibitors\/. Accessed 20 Jan 2021."},{"key":"1479_CR7","unstructured":"Athenex. Athenex announces FDA approval of Klisyri\u00ae (tirbanibulin) for the treatment of actinic keratosis on the face or scalp [media release]. 15 Dec 2020. http:\/\/www.athenex.com."},{"key":"1479_CR8","unstructured":"Athenex. Tirbanibulin (Klisyri\u00ae): US highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213189s000lbl.pdf. Accessed 20 Jan 2021."},{"key":"1479_CR9","unstructured":"Athenex. Athenexs partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis [media release]. 2 Mar 2020. http:\/\/www.athenex.com."},{"key":"1479_CR10","unstructured":"Kinex Pharmaceuticals L. L. C., Hanmi Pharmaceutical. Hanmi Pharmaceuticals to acquire the rights for a promising phase II anti-cancer Src kinase\/pretubulin dual inhibitor from Kinex Pharmaceuticals, in selected asian territories [media release]. 20 Apr 2011. http:\/\/www.kinexpharma.com."},{"key":"1479_CR11","unstructured":"Athenex, Hanmi Pharmaceutical. Athenex and its collaborative partner, Hanmi Pharmaceutical, announce strategic realignment of their joint projects [media release]. 12 Sept 2018. http:\/\/www.athenex.com."},{"key":"1479_CR12","unstructured":"Kinex Pharmaceuticals L. L. C., PharmaEssentia Corp. PharmaEssentia acquires certain asian rights for dermatology preparations of Kinex Pharmaceuticals' promising novel dual Src\/pretubulin inhibitor, KX01 [media release]. 3 Dec 2012. http:\/\/www.kinexpharma.com."},{"key":"1479_CR13","unstructured":"Athenex. Athenex and PharmaEssentia announce positive early signals of clinical activity of KX2-391 (INN: tirbanibulin) in patients with psoriasis [media release]. 7 Jun 2019. http:\/\/www.athenex.com."},{"key":"1479_CR14","unstructured":"PharmaEssentia Corporation. PharmaEssentia and Athenex agree on product development rights as part of strategic realignment [media release]. 27 Jan 2017. http:\/\/www.pharmaessentia.com."},{"key":"1479_CR15","unstructured":"Almirall SA. Almirall and Athenex announce strategic partnership for the treatment of actinic keratosis [media release]. 11 Dec 2017. http:\/\/www.almirall.com."},{"key":"1479_CR16","unstructured":"Athenex. Athenex expands its strategic partnership with Guangzhou Xiangxue Pharmaceutical through a licensing agreement for its product candidates oral paclitaxel and oral irinotecan, as well as tirbanibulin ointment, in China, Hong Kong and Macao [media release]. 16 Dec 2019. http:\/\/www.athenex.com."},{"issue":"6","key":"1479_CR17","first-page":"s199","volume":"4","author":"R Yavel","year":"2020","unstructured":"Yavel R, Overcash JS, Zhi J, et al. Phase I maximal use pharmacokinetic study of tirbanibulin ointment 1% in subjects with actinic keratosis [poster]. SKIN J Cutan Med. 2020;4(6):s199.","journal-title":"SKIN J Cutan Med."},{"issue":"6","key":"1479_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384(6):512\u201320.","journal-title":"N Engl J Med."},{"issue":"7 Suppl","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.jid.2020.05.006","volume":"140","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Kempers S, Puig S, et al. Tirbanibulin, a novel inhibitor of tubulin polymerisation and src kinase signaling, for actinic keratosis (AK): results of two phase-3 studies and 1-year follow-up data [abstract no. LB918]. J Investig Dermatol. 2020;140(7 Suppl):B3.","journal-title":"J Investig Dermatol."},{"issue":"11","key":"1479_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.36849\/JDD.2020.5576","volume":"19","author":"S Kempers","year":"2020","unstructured":"Kempers S, DuBois J, Forman S, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results. J Drugs Dermatol JDD. 2020;19(11):1093\u2013100.","journal-title":"J Drugs Dermatol JDD."},{"issue":"3 Suppl 1","key":"1479_CR21","first-page":"AB220","volume":"79","author":"M Jarratt","year":"2018","unstructured":"Jarratt M, Kempers S, Forman S, et al. Phase II study of KX2-391 ointment 1%, a novel field treatment for actinic keratosis, based on Src\/tubulin polymerization inhibition [abstract no. 6134]. J Am Acad Dermatol. 2018;79(3 Suppl 1):AB220.","journal-title":"J Am Acad Dermatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01479-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-021-01479-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01479-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T14:33:15Z","timestamp":1616250795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-021-01479-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01479-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"13 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis International Ltd\/Springer Nature and S. Duggan is a salaried employee of Adis International Ltd\/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}